Video

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

Author(s):

Axel Hoos, MD, PhD

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Gursel Aktan, MD, PhD
September 20th 2024

Pembrolizumab-Based Regimens Earn Positive CHMP Opinion in Endometrial and Cervical Cancers

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Richard Vile, PhD, Mayo Clinic
September 18th 2024

Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Carlo B. Bifulco, MD, medical director of oncological molecular pathology and pathology informatics at the Providence Oregon Regional Laboratory and CMO of Providence Genomics
September 16th 2024

GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers